BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA ...

No significant safety or dose limiting toxicities have been reported BOSTON, March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more ...

TransCode Therapeutics (NASDAQ:RNAZ) announces to raise $10M through the purchase and sale of 10.25M shares of its common stock and warrants to purchase up to 10.25M shares of common stock priced ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an RNA oncology company with a current market capitalization of $12.21 million, has announced the initiation of dosing the first patient in ...

(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) Monday has entered an agreement to sell 10.25 million shares of common stock and an equal number of warrants at $0.98 per unit, in compliance with ...

Our critic calls his survey “scintillating and sweeping.” By Holland Cotter The Museum of Modern Art in New York is promoting Christophe Cherix, the chief curator of its drawings and prints ...

We’re mining the archives for some of Robin Abrahams’s hit columns you may have missed (this one is from 2005). On a recent restaurant visit, the ladies lunching next to my father and me spoke ...

BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA ...

TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to ...